Remus Pharmaceuticals Share Price Today

Remus Pharmaceuticals appoints Bhavik Shah as CFO effective July 9, 2026

Remus Pharmaceuticals appointed Bhavik Shah as Chief Financial Officer effective July 9, 2026, following Anjali Shah's resignation. Shah, a Chartered Accountant with over 20 years of experience, will oversee finance, accounts, and regulatory compliance. The Board approved the appointment based on committee recommendations.

Remus Pharmaceuticals unit faces IRS penalty of USD 14,247.38

Remus Pharmaceuticals' stepdown subsidiary Espee Biopharma & Finechem LLC was penalised USD 14,247.38 by the IRS for alleged tax non-payment and late filing. The subsidiary disputes the penalty, claiming taxes were paid, and is engaging with the IRS for corrections. The company confirmed no material impact on its financials or operations.

Remus Pharmaceuticals FY26 net profit rises 20% to ₹46 crore

Remus Pharmaceuticals reported a 20% YoY rise in FY26 net profit to ₹46 crore, with revenue growing 38% to ₹854 crore. The B2C segment's revenue contribution increased to 14%, driven by new product launches in Latin America. The company plans to expand its B2C segment further in FY27 and has initiated filings for semaglutide in emerging markets.

Remus FY26 PAT rises 20% to ₹46.17 Cr, declares dividend

Remus Pharmaceuticals reported a 37.6% YoY increase in revenue to ₹853.63 Cr for FY26, with PAT growing 20.2% to ₹46.17 Cr. The company declared a final dividend of ₹0.50 per share and expanded into four new markets during H2 FY26.

Remus Pharmaceuticals posts FY26 earnings call audio

Remus Pharmaceuticals Limited has released the audio recording of its earnings conference call regarding the financial results for the year ended March 31, 2026. The call, held on May 21, 2026, is available on the company's website. No unpublished price sensitive information was disclosed during the session.

Remus Pharmaceuticals appoints Tapan Shah as Secretarial Auditor

Remus Pharmaceuticals Limited appointed Mr. Tapan Shah as Secretarial Auditor for FY 2026-2027 on May 20, 2026. The Board approved the appointment based on the Audit Committee's recommendation. Mr. Shah brings over two decades of experience in corporate and regulatory compliance.